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AbstrAct
Objective
To evaluate the accuracy of the depression subscale of 
the Hospital Anxiety and Depression Scale (HADS-D) 
to screen for major depression among people with 
physical health problems.
Design
Systematic review and individual participant data 
meta-analysis.
Data sOurces
Medline, Medline In-Process and Other Non-Indexed 
Citations, PsycInfo, and Web of Science (from 
inception to 25 October 2018).
review methODs
Eligible datasets included HADS-D scores and major 
depression status based on a validated diagnostic 
interview. Primary study data and study level data 
extracted from primary reports were combined. For 
HADS-D cut-off thresholds of 5-15, a bivariate random 
effects meta-analysis was used to estimate pooled 
sensitivity and specificity, separately, in studies 
that used semi-structured diagnostic interviews 
(eg, Structured Clinical Interview for Diagnostic 
and Statistical Manual of Mental Disorders), fully 
structured interviews (eg, Composite International 
Diagnostic Interview), and the Mini International 
Neuropsychiatric Interview. One stage meta-
regression was used to examine whether accuracy was 
associated with reference standard categories and the 
characteristics of participants. Sensitivity analyses 
were done to assess whether including published 
results from studies that did not provide raw data 
influenced the results.
results
Individual participant data were obtained from 101 of 
168 eligible studies (60%; 25 574 participants (72% 
of eligible participants), 2549 with major depression). 
Combined sensitivity and specificity was maximised at 
a cut-off value of seven or higher for semi-structured 
interviews, fully structured interviews, and the Mini 
International Neuropsychiatric Interview. Among 
studies with a semi-structured interview (57 studies, 
10 664 participants, 1048 with major depression), 
sensitivity and specificity were 0.82 (95% confidence 
interval 0.76 to 0.87) and 0.78 (0.74 to 0.81) for a 
cut-off value of seven or higher, 0.74 (0.68 to 0.79) 
and 0.84 (0.81 to 0.87) for a cut-off value of eight 
or higher, and 0.44 (0.38 to 0.51) and 0.95 (0.93 to 
0.96) for a cut-off value of 11 or higher. Accuracy was 
similar across reference standards and subgroups 
and when published results from studies that did not 
contribute data were included.
cOnclusiOns
When screening for major depression, a HADS-D 
cut-off value of seven or higher maximised combined 
sensitivity and specificity. A cut-off value of eight or 
higher generated similar combined sensitivity and 
specificity but was less sensitive and more specific. 
To identify medically ill patients with depression 
with the HADS-D, lower cut-off values could be used 
to avoid false negatives and higher cut-off values to 





Major depressive disorder is present in 10-20% of 
patients with acute or chronic medical conditions 
and is associated with a poor prognosis.1-6 Healthcare 
providers in non-psychiatric settings, where most of the 
care for depression is provided, might have relatively 
little formal mental health training.7 Mental healthcare 
could be inconsistently delivered, particularly outside 
of primary care.8 9 Many depressed patients are not 
identified, and a high proportion of patients treated for 
depression do not meet diagnostic criteria.10-12
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WhAt Is AlreAdy knoWn on thIs topIc
The Hospital Anxiety and Depression Scale Depression subscale (HADS-D) is the 
most commonly used screening tool for depression in medically ill patients, with 
cut-off values of eight or higher or 11 or higher used as standards to identify 
possible or probable depression
The only previous meta-analysis on the accuracy of HADS for detecting major 
depression in all populations included 11 studies (1735 participants) up to 
2006
WhAt thIs study Adds
At a HADS-D cut-off value of seven or higher, combined sensitivity and specificity 
were maximised (82%, 78%), based on 101 studies; sensitivity and specificity 
were 74% and 84% for a HADS-D cut-off value of eight or higher and 44% and 
95% for a cut-off value of 11 or higher 
Results did not differ across reference standards or participant characteristics, 
including age, sex, human development index levels, and recruitment setting of 
participants 
A web based knowledge translation tool is available to estimate the expected 
number of positive screens, and true and false screening outcomes based on 
study results (depressionscreening100.com/hads-d)
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Recognising depression can be particularly difficult 
in people with a physical illness, and some symptoms, 
such as fatigue, changes in appetite, and trouble 
sleeping, are common in both depression and many 
medical conditions.7 Although controversial, screening 
for depression is sometimes used to identify people not 
previously recognised as having depression, including 
in chronic conditions and cancer.13-19 Screening for 
depression involves giving short questionnaires to 
people not already known or suspected of having 
depression, with cut-off thresholds on the screening 
questionnaires to distinguish positive from negative 
screening results, and then assessing those with 
positive results further to determine whether the 
criteria for depression are met.14-18
The Hospital Anxiety and Depression Scale (HADS)20 
was developed to help identify anxiety disorders and 
depression in people with a physical illness. To avoid 
overlap with physical disorders, the HADS does not 
include somatic symptoms, such as insomnia, loss of 
appetite, or fatigue. The depression subscale of the 
HADS (HADS-D) is the most commonly used screening 
tool for depression in medically ill patients21 and is 
one of several validated measures recommended for 
assessing the severity of depressive symptoms by the 
United Kingdom National Institute for Health and Care 
Excellence (NICE).22 In the initial HADS-D validation 
study (100 participants, 12 with major depression),20 
which has been cited over 37 000 times since 
publication in 1983 (Google Scholar), the developers 
suggested that a cut-off value of eight or higher could 
be used to identify possible depression and a cut-off 
value of 11 or higher for probable depression. These 
cut-off values have since been used as standards in 
research and practice.23-25
Primary studies on the accuracy of HADS-D 
screening have been limited by samples too small 
to generate precise estimates; inability to conduct 
subgroup analyses; selective reporting of results from 
study specific “optimal cut-off values” that seem 
more accurate than standard cut-off values in a given 
sample; and including patients who would not be 
screened in practice because of a previous diagnosis 
or treatment for depression.23-29 The only previous 
meta-analysis on the accuracy of the HADS-D for 
detecting major depression that was not restricted to 
subpopulations (eg, cancer, palliative care) included 
11 eligible studies (1735 participants) up to June 
2006.23 Analyses of accuracy at cut-off values from 
eight or higher to 11 or higher were based on only 
six to seven studies, however, because not all of the 
11 studies reported results for each cut-off value. 
Overall, 39% of otherwise eligible studies could not be 
included in any meta-analyses of the HADS-D or HADS 
for anxiety because results for commonly used cut-off 
values were not reported. Subgroup analyses were not 
possible because they were not available in primary 
studies. Also, results were combined across reference 
standard diagnostic interviews, even though important 
differences in design and structure exist. Recent studies 
have shown that different diagnostic interview formats 
have substantively different likelihoods of classifying 
major depression.30-33
An individual participant data meta-analysis 
(IPDMA)34 involves a standard systematic review, 
followed by synthesis of line-by-line participant 
data from primary studies, rather than aggregated 
summary data. The advantages of an IPDMA with the 
HADS-D are the ability to include data from studies 
that administered the HADS-D and a diagnostic 
interview but did not publish accuracy results; to 
carry out subgroup analyses; to evaluate results 
excluding participants already diagnosed with or 
treated for depression who would not be screened in 
practice; and overcoming bias from selective cut-off 
reporting by including estimates of accuracy for all of 
the relevant cut-off values from the studies included 
in the meta-analysis. Our objectives were to evaluate 
the accuracy of the HADS-D to screen for depression, 
separately by different types of reference standards, 
prioritising semi-structured interviews; and to 
investigate whether accuracy differed according to age, 
sex, medical condition, country human development 
index, and recruitment setting or according to whether 
patients with previously diagnosed depression were 
included.
Methods
This IPDMA was registered in PROSPERO (CRD-
42015016761), a protocol was published,35 and the 
results were described according to the reporting 
guidelines of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses of diagnostic 
test accuracy (PRISMA-DTA)36 and PRISMA of individual 
participant data (PRISMA-IPD).37 The methods were 
similar to our previously published IPDMAs of the 
accuracy of the Patient Health Questionaire-938 and 
the Edinburgh Postnatal Depression Scale.39
Dataset eligibility
Datasets from articles in any language were eligible if 
they included a diagnostic classification for current 
major depressive disorder or major depressive 
episode according to the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM)40-43 or the 
International Classification of Diseases (ICD)44 based 
on a validated semi-structured or fully structured 
interview; total scores for the HADS-D were included; 
the diagnostic interview and HADS-D were done 
within two weeks of each other, because the diagnostic 
criteria of the DSM and ICD for major depression 
specify that symptoms must have been present in the 
past two weeks; participants were aged 18 or older and 
were not recruited from youth or psychiatric settings; 
and participants were not recruited because they were 
identified as having symptoms of depression because 
screening is done to identify previously undiagnosed 
patients. Datasets where not all participants were 
eligible were included if the primary data allowed 
selection of eligible participants.
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search strategy and study selection
A medical librarian searched Medline, Medline In-
Process and Other Non-Indexed Citations, and PsycInfo 
through OvidSP, and Web of Science through ISI Web 
of Knowledge, from inception to 25 October 2018 with 
a peer reviewed45 search strategy (supplementary 
methods A). We also reviewed reference lists of relevant 
reviews and queried contributing authors about non-
published studies. Search results were uploaded into 
RefWorks (RefWorks-COS, Bethesda, MD, USA). After 
de-duplication, unique citations were uploaded into 
DistillerSR (Evidence Partners, Ottawa, ON, Canada) 
for tracking search results.
Pairs of investigators independently reviewed titles 
and abstracts for eligibility. If either believed that a 
study was potentially eligible, a full text review was 
done by pairs of investigators independently, with 
disagreements resolved by consensus, consulting a 
third investigator when necessary. Translators were 
consulted if team members were not fluent in the 
language of an article.
Data contribution, extraction, and synthesis
Authors of eligible datasets were invited to contribute 
de-identified primary data. We emailed corresponding 
authors of eligible primary studies at least three 
times, if necessary. If we did not receive a response, 
we emailed coauthors and attempted to contact 
corresponding authors by telephone.
Diagnostic interview and country were extracted 
from published reports by pairs of investigators 
independently, with disagreements resolved by 
consensus. Countries were categorised as “very high,” 
“high”, or “low-medium” development based on the 
United Nation’s human development index for the 
country, for the year the study was published. The 
human development index is a statistical composite 
index that includes indicators of life expectancy, 
education, and income.46 Participant level data 
extracted from the studies in the meta-analysis included 
age, sex, diagnosis of cancer, patient care setting, 
HADS-D scores, and major depression status (with 
or without major depression). We focused on cancer 
and not other medical conditions because not enough 
studies or data existed for analyses of other conditions. 
For defining major depression, we considered major 
depressive disorder or major depressive episode based 
on the DSM or ICD. If more than one was reported, 
we prioritised major depressive episode over major 
depressive disorder because screening would attempt to 
detect depressive episodes and further interview would 
determine if the episode was related to major depressive 
disorder, bipolar disorder, or persistent depressive 
disorder. We prioritised the DSM over the ICD.
Individual participant data were converted to a 
standard format and combined into one dataset 
with study level data. We compared the published 
characteristics of the participants and the estimates 
of the accuracy of the diagnoses with the results from 
the raw datasets and resolved any discrepancies by 
consulting the original investigators.
risk of bias assessment
Risk of bias of the studies included in the meta-analysis 
was assessed by two investigators independently 
with the QUality Assessment of Diagnostic Accuracy 
Studies-2 tool (QUADAS-2; supplementary methods 
B).47 Any discrepancies were resolved by consensus, 
and a third investigator was involved if necessary. Risk 
of bias was coded at both the study and participant 
levels because some data (eg, time between index test 
and reference standard) might have differed among 
participants from the same study.
statistical analyses
We conducted three sets of analyses. Firstly, we 
separately pooled estimated sensitivity and specificity 
across HADS-D cut-off values for studies that used semi-
structured reference standard interviews (Structured 
Clinical Interview for the DSM (SCID),48 Schedules for 
Clinical Assessment in Neuropsychiatry,49 Schedule 
for Affective Disorders and Schizophrenia,50 Monash 
Interview for Liaison Psychiatry51), fully structured 
interviews (Composite International Diagnostic 
Interview (CIDI),52 Diagnostic Interview Schedule53), 
and the Mini International Neuropsychiatric Interview 
(MINI).54 55 The MINI was treated as a separate 
reference standard category throughout all analyses. 
We analysed studies that used different types of 
reference standards separately because they have 
different designs and performance characteristics. We 
found in previous IPDMAs that, compared with the 
semi-structured SCID interview, participants evaluated 
with the brief MINI were substantially more likely to 
be classified as having major depression. When the 
fully structured CIDI was used, participants with lower 
depressive symptom severity were more likely to be 
classified with major depression, but the opposite 
was true in those with greater symptom severity.30-33 
Semi-structured interviews should be carried out by 
experienced diagnosticians and are considered to most 
closely replicate clinical diagnostic procedures.56-58
For each reference standard category (semi-
structured, fully structured, and the MINI), for 
HADS-D cut-off values of 5-15 separately, bivariate 
random effects models were fitted from Gauss-Hermite 
quadrature.59 This two stage meta-analytic approach 
models sensitivity and specificity simultaneously and 
accounts for the correlation between them and the 
precision of estimates within studies. We constructed 
empirical receiver operating characteristic curves 
based on pooled sensitivity and specificity estimates, 
and calculated area under the curve values for each 
reference standard category. Also, we conducted one 
stage meta-regressions with interactions between 
reference standard category (reference category: semi-
structured) and accuracy coefficients (logit(sensitivity) 
and logit(1−specificity)). To present positive and 
negative predictive values for the cut-off value that 
maximised combined sensitivity and specificity, and 
for standard cut-off values of eight or higher and 11 
or higher, we generated nomograms for an assumed 
prevalence of major depression of 5-25% (based on 
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the prevalence of major depressive disorder in medical 
patients of 10-20% ±5%).1-6
To investigate heterogeneity, for each category 
of reference standard we generated forest plots of 
sensitivity and specificity for each study for the cut-
off value that maximised combined sensitivity and 
specificity. Although no well established methods 
exist to quantify levels of heterogeneity in diagnostic 
test accuracy meta-analyses,36 60 we quantified 
heterogeneity by reporting estimated variances of the 
random effects for sensitivity and specificity (τ2) and 
by estimating R, the ratio of the estimated standard 
deviation of the pooled sensitivity (or specificity) 
from the random effects model to that from the 
corresponding fixed effects model.61
Secondly, to investigate whether the accuracy 
of HADS-D screening differs according to the 
characteristics of the participants, we conducted 
one stage meta-regressions separately by reference 
standard category (semi-structured, fully structured, 
and the MINI), where we interacted all subgroup 
variables (age (measured continuously), sex (reference 
category=female)), country human development index 
(reference category=very high), diagnosis of cancer 
(reference category=no), and recruitment setting for 
participants (reference category=inpatient specialty 
care) with logit(sensitivity) and logit(1−specificity). 
These models were restricted to the subset of studies 
that had complete data for all relevant variables. This 
method resulted in a loss of 520 (8%) participants that 
did not have data for age or sex from semi-structured 
interview studies, two participants (0.1%) from fully 
structured interview studies, and 88 participants 
(1%) from MINI studies. Also, for each reference 
standard, we estimated sensitivity and specificity in 
participants verified as not having been diagnosed or 
receiving treatment for mental health problems, and 
we compared the accuracy results with the results 
in all participants. This comparison was conducted 
because in practice, screening is done to identify 
previously undiagnosed people with major depression. 
Screening is never done in participants currently 
diagnosed or receiving treatment for mental health 
problems. The inclusion of patients who would not 
be screened in practice could bias the estimates of 
diagnostic accuracy, but many primary studies did 
not record the diagnostic or treatment status of the 
participants. Thus we evaluated whether results with 
all participants differed from results when only studies 
and participants where treatment and diagnostic 
status were known were analysed. Analytically, we 
calculated the confidence intervals of the differences 
by bootstrapping to account for the overlap in the two 
groups being compared.
For analysis of the possible influence of risk of 
bias, we added interactions of QUADAS-2 signalling 
item responses with logit(sensitivity) and logit(1−
specificity) to the main one stage meta-regression 
models in each reference standard category separately. 
This method allowed us to compare the accuracy 
of the HADS-D by subgroups based on QUADAS-2 
items for all items with at least 100 participants with 
major depression and 100 without major depression, 
categorised as having a low versus an unclear or high 
risk of bias.
Thirdly, in sensitivity analyses, we combined the 
accuracy results of the IPDMA with published results 
from studies that did not contribute individual 
participant data for each reference standard category, 
semi-structured, fully structured, and the MINI. Based 
on the publication of eligible accuracy results from 
studies that did not contribute data, we conducted 
this analysis for a HADS-D cut-off value of eight or 
higher in studies that used a semi-structured reference 
standard; for HADS-D cut-off values of eight or higher 
and 11 or higher in studies that used a fully structured 
reference standard; and for HADS-D cut-off values of 
eight or higher and 11 or higher in studies that used 
the MINI. All analyses were done in R (R version R 
3.4.162 and R Studio version 1.0.14363) with the glmer 
function within the lme4 package.64
Patient and public involvement
No patients were involved in the initial development 
of the research question, outcome measures, or study 
design. Since study inception, Dr Sarah Markham has 
joined the DEPRESSD group as a patient collaborator. 
She provided comments on the draft manuscript. 
We have no plans to disseminate the results of the 
research to study participants or the relevant patient 
communities. An online knowledge translation tool, 
intended for clinicians (the end users of the HADS-D 
screening tool) and other interested parties, however, 
has been made available at depressionscreening100.
com/hads-d. The tool allows clinicians to estimate 
the expected number of positive screens as well as 
true and false screening outcomes based on study 
results.
results
search results and dataset inclusion
We found 12 830 unique titles and abstracts from the 
database search. Of these, 12 300 were excluded after 
review of the title and abstract and 301 after a full text 
review (fig 1), resulting in 229 eligible articles from 
158 unique participant samples. Of these, 92 (58%) 
contributed datasets (fig 1). Among 14 eligible studies 
published before 2000, only one (7%) contributed 
a dataset; in studies published between 2000 and 
2009, 31 of 57 (54%) contributed datasets; and 
in studies published between 2010 and 2018, 60 
of 87 (69%) contributed datasets. Supplementary 
table A provides the reasons for exclusion of the 301 
articles after a full text review. Authors of the studies 
included in the meta-analysis contributed data from 
10 other studies that the search did not retrieve, 
for a total of 102 datasets. Supplementary table B 
shows the characteristics of the primary studies that 
contributed data and the eligible studies that did not 
provide datasets. Of 31 535 participants in 168 eligible 
published studies, 22 600 (72%) were included. One 
dataset initially included was excluded from this study 
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because it had no participants with major depression 
and therefore could not be included in the bivariate 
random effects models. Thus a total of 101 datasets 
(22 574 participants, 2549 with major depression) 
were included in this study.
Of the 101 studies included, 57 used semi-structured 
reference standards, including 53 that used the 
SCID; 12 used fully structured reference standards 
(excluding the MINI), including 11 that used the CIDI; 
and 32 used the MINI (table 1 and table 2).




No validated interview to assess major depression
>2 weeks between HADS and diagnostic interview











Unique titles and abstracts identified and screened for potential eligibility
Titles and abstracts excluded
Full text articles reviewed for eligibility
Articles meeting eligibility criteria
301
Eligible studies did not provide primary data
Published diagnostic accuracy results eligible for sensitivity analyses




Unique studies meeting eligibility criteria
158
HADS datasets with primary data
102
HADS studies included in this study
101




HADS studies that used
MINI as reference standard
71
Dataset had no patients with major depression
66
92
Unpublished studies or articles did not
come up in search (provided by authors
of published eligible studies)
10
32
HADS studies with a (non-MINI)
fully structured diagnostic
interview as reference standard
12
HADS studies with a
semi-structured diagnostic




Fig 1 | Flow diagram of study selection process. haDs=hospital anxiety and Depression scale; mini=mini 
international neuropsychiatric interview
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haDs-D sensitivity and specificity by reference 
standard category
Table 3 shows the sensitivity and specificity estimates 
for cut-off values of 5-15 by reference standard 
category. Combined sensitivity and specificity was 
maximised at a cut-off value of seven or higher for semi-
structured interviews, fully structured interviews, and 
the MINI. For semi-structured interviews, sensitivity 
and specificity were 0.82 (95% confidence interval 
0.76 to 0.87) and 0.78 (0.74 to 0.81) for a cut-off 
value of seven or higher, 0.74 (0.68 to 0.79) and 0.84 
(0.81 to 0.87) for a cut-off value of eight or higher, 
and 0.44 (0.38 to 0.51) and 0.95 (0.93 to 0.96) for a 
cut-off value of 11 or higher. Figure 2 shows receiver 
operating characteristic curves and area under the 
curve values. The area under the curve was 0.87 for 
semi-structured interviews, 0.85 for fully structured 
diagnostic interviews, and 0.83 for the MINI. We found 
no significant differences in accuracy by reference 
standard category that held across all cut-off values 
(supplementary table C).
Of the 66 published studies that did not contribute 
datasets, 16 published eligible accuracy results but 
only 12 published results for cut-off values of seven or 
higher, eight or higher, or 11 or higher (supplementary 
table B2; semi-structured interview=8, fully structured 
interview=2, MINI=2). Supplementary tables D1-D3 
show that estimates were similar when these results 
were included.
Figure 3 shows nomograms of positive and negative 
predictive values for cut-off values of seven or higher, 
eight or higher, and 11 or higher for the semi-structured 
reference standard. For a prevalence of major 
depression of 5-25%, positive predictive values for a 
cut-off value of seven or higher compared with semi-
structured interviews ranged from 17% to 56%, and 
negative predictive values ranged from 93% to 99%. 
Positive predictive values ranged from 20% to 61% for 
a cut-off value of eight or higher and from 32% to 75% 
for a cut-off value of 11 or higher; negative predictive 
values ranged from 91% to 98% for a cut-off value of 
eight or higher and from 84% to 97% for a cut-off value 
of 11 or higher. Ranges were similar for fully structured 
and MINI reference standard interviews.
Heterogeneity analyses suggested moderate hetero-
geneity across the studies. Supplementary figure A 
shows forest plots of sensitivity and specificity, and 
supplementary table E shows τ2 and R values.
haDs-D accuracy among subgroups and by risk of 
bias
Sensitivity and specificity estimates were not signifi-
cantly different for participants identified as not 
currently diagnosed or receiving mental health 
treatment compared with all participants across 
reference standard categories (supplementary table F). 
We found no significant differences in accuracy that 
were consistent across reference standard categories 
table 1 | Participant data by diagnostic interview
Diagnostic interview no of studies no of participants major depression (no (%))
Semi-structured
 SCID 53 10 029 983 (10)
 SCAN 1 50 12 (24)
 SADS 1 56 9 (16)
 MILP 2 529 44 (8)
Fully structured 
 CIDI 11 3705 327 (9)
 DIS 1 194 11 (6)
MINI 32 8011 1163 (15)
Total 101 22 574 2549 (11)
CIDI=Composite International Diagnostic Interview; DIS= Diagnostic Interview Schedule; MILP= Monash 
Interview for Liaison Psychiatry; MINI=Mini International Neuropsychiatric Interview; SADS=Schedule for Affective 
Disorders and Schizophrenia; SCAN=Schedules for Clinical Assessment in Neuropsychiatry; SCID=Structured 
Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders.
table 2 | Participant data by subgroup*
Participant subgroup
semi-structured diagnostic interviews Fully structured diagnostic interviews mini
no of 
studies
















All participants 57 10 664 1048 (10) 12 3899 338 (9) 32 8011 1163 (15)
Participants not currently 
diagnosed or receiving 
treatment for a mental  
health problem
23 3354 204 (6) 3 2069 123 (6) 13 2590 262 (10)
Age <60 52 5827 655 (11) 12 2274 257 (11) 31 4879 722 (15)
Age ≥60 52 4690 340 (7) 10 1623 81 (5) 32 3045 427 (14)
Women 55 6123 619 (10) 12 1807 179 (10) 32 3874 675 (17)
Men 52 4450 397 (9) 11 2092 159 (8) 29 4132 488 (12)
Very high country human 
development index 54 10 528 1013 (10) 8 3453 227 (7) 28 7684 1077 (14)
High country human  
development index 3 136 35 (26) 4 446 111 (25) 4 327 86 (26)
Participants diagnosed  
with cancer 17 3084 247 (8) 6 2058 123 (9) 4 663 67 (10)
Inpatient specialty care 35 6008 631 (11) 9 2040 145 (7) 12 5390 806 (15)
Outpatient specialty care 19 3650 466 (13) 5 1859 193 (10) 16 1826 305 (17)
Non-medical care 4 1225 82 (7) — — — 3 695 35 (5)
Inpatient and  
outpatient mixed 2 320 34 (11)
— — — 1 100 17 (17)
MINI=Mini International Neuropsychiatric Interview.
*Some variables were coded at the study level and others at the participant level and so the number of studies does not always add up to the total number in the reference category.
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for any participant characteristic (supplementary 
table G).
Supplementary table H shows QUADAS-2 ratings for 
the studies included. No QUADAS-2 domain items were 
consistently associated with differences in estimates of 
sensitivity or specificity for the semi-structured, fully 
structured, and MINI reference standard categories 
(supplementary table G).
discussion
Our main finding was that combined sensitivity (82%) 
and specificity (78%) was maximised at a HADS-D 
cut-off value of seven or higher among 57 studies that 
used semi-structured interviews, which are designed 
to be used by trained mental health professionals to 
replicate diagnostic procedures as closely as possible. 
At cut-off values of eight or higher and 11 or higher, 
which are often recommended for screening for 
depression,22 sensitivity and specificity were 74% and 
84%, and 44% and 95%, respectively.
For the cut-off values that we examined, HADS-D 
sensitivity was 1-11% higher compared with semi-
structured interviews than fully structured interviews 
(excluding the MINI), and 4-11% higher when 
compared with the MINI. Specificity estimates were 
similar across different reference standards. We 
found no significant differences in accuracy between 
subgroups that replicated across reference standard 
categories, although some subgroups had limited 
numbers of participants and patients. The results 
did not differ when patients previously diagnosed as 
having depression or receiving treatment for a mental 
health problem were excluded.
In the only previous general HADS-D meta-
analysis,23 which aggregated published data from 11 
studies and combined reference standards without 
adjustment, sensitivity and specificity were 0.82 
(95% confidence interval 0.73 to 0.89) and 0.74 
(0.60 to 0.84) for a cut-off value of eight or higher 
and 0.56 (0.40 to 0.71) and 0.92 (0.79 to 0.97) for 
a cut-off value of 11 or higher. The results were not 
reported for a cut-off value of seven or higher. Our 
results differed substantially. Of the 57 studies that 
used semi-structured interviews, pooled sensitivity for 
HADS-D was lower and specificity was higher for the 
recommended cut-off values of eight or higher and 11 
or higher. Differences in results between our IPDMA 
and the previous meta-analysis might be because our 
meta-analysis included a much larger number (101 
v 11) of primary studies, including 57 with a semi-
structured reference standard, and incorporated data 
from all cut-off values for all of the studies included. 
In contrast, the previous general HADS-D aggregate 
data meta-analysis,23 and two other meta-analyses 
that used subsets of studies of people with cancer or 
in palliative care,24 25 combined reference standards 
without adjustment and only included studies that 
reported results on commonly used cut-off values 
of eight or higher and 11 or higher,23 or fitted one 
bivariate accuracy model that included results from 
different optimal cut-off values from different primary 
studies.24 25
The finding that the combined sensitivity and 
specificity of the HADS-D was highest when compared 


















Fig 2 | receiver operating characteristic (rOc) curves and area under the curve (auc) 
values for each reference standard category. rOc curves comparing sensitivity and 
specificity estimates for the hospital anxiety and Depression scale Depression 
subscale (haDs-D) cut-off values of 5-15 (points represent cut-off values of 5 (right) 
to 15 (left)) among semi-structured diagnostic interviews, fully structured diagnostic 
interviews, and the mini international neuropsychiatric interview (mini), with auc 
values
table 3 | comparison of sensitivity and specificity estimates for each reference standard category
cut-off
semi-structured reference standard* Fully structured reference standard† mini reference standard‡
sensitivity (95% ci) specificity (95% ci) sensitivity (95% ci) specificity (95% ci) sensitivity (95% ci) specificity (95% ci)
5 0.92 (0.87 to 0.95) 0.61 (0.57 to 0.66) 0.89 (0.76 to 0.95) 0.57 (0.46 to 0.67) 0.88 (0.84 to 0.91) 0.63 (0.60 to 0.66)
6 0.88 (0.83 to 0.92) 0.70 (0.66 to 0.74) 0.86 (0.73 to 0.93) 0.66 (0.55 to 0.76) 0.82 (0.78 to 0.85) 0.72 (0.69 to 0.75)
7 0.82 (0.76 to 0.87) 0.78 (0.74 to 0.81) 0.81 (0.67 to 0.9) 0.73 (0.63 to 0.81) 0.75 (0.70 to 0.79) 0.80 (0.77 to 0.82)
8 0.74 (0.68 to 0.79) 0.84 (0.81 to 0.87) 0.70 (0.56 to 0.81) 0.83 (0.72 to 0.90) 0.66 (0.61 to 0.71) 0.86 (0.84 to 0.88)
9 0.64 (0.58 to 0.69) 0.88 (0.86 to 0.91) 0.59 (0.48 to 0.70) 0.88 (0.79 to 0.94) 0.55 (0.49 to 0.60) 0.91 (0.89 to 0.92)
10 0.55 (0.49 to 0.60) 0.92 (0.90 to 0.94) 0.48 (0.39 to 0.56) 0.92 (0.85 to 0.96) 0.44 (0.38 to 0.50) 0.93 (0.92 to 0.95)
11 0.44 (0.38 to 0.51) 0.95 (0.93 to 0.96) 0.37 (0.30 to 0.45) 0.94 (0.89 to 0.97) 0.34 (0.29 to 0.40) 0.96 (0.95 to 0.97)
12 0.35 (0.29 to 0.41) 0.96 (0.95 to 0.97) 0.25 (0.19 to 0.34) 0.96 (0.92 to 0.98) 0.28 (0.23 to 0.34) 0.97 (0.96 to 0.98)
13 0.27 (0.22 to 0.32) 0.98 (0.97 to 0.98) 0.19 (0.14 to 0.25) 0.97 (0.94 to 0.98) 0.19 (0.15 to 0.25) 0.98 (0.98 to 0.99)
14§ 0.20 (0.16 to 0.25) 0.99 (0.98 to 0.99) 0.09 (0.04 to 0.19) 0.98 (0.96 to 0.99) 0.15 (0.15 to 0.15) 0.99 (0.99 to 0.99)
15 0.15 (0.11 to 0.19) 0.99 (0.99 to 1.00) 0.07 (0.03 to 0.14) 0.98 (0.97 to 0.99) 0.10 (0.08 to 0.14) 0.99 (0.99 to 1.00)
MINI=Mini International Neuropsychiatric Interview. 
*Number of studies, participants, and participants with major depression are 57, 10 664, and 1048, respectively.
†Number of studies, participants, and participants with major depression are 12, 3899, and 338, respectively.
‡Number of studies, participants, and participants with major depression are 32, 8011, and 1163, respectively.
§Among studies with the MINI, the default optimiser in glmer failed at this cut-off value and bobyqa was used instead.
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with our previous results in IPDMAs that assessed the 
accuracy of other screening tools, including the Patient 
Health Questionnaire-938 and the Edinburgh Postnatal 
Depression Scale.39 Ideally, data from studies that 
used different reference standards could be combined 
but the different diagnostic characteristics of different 
types of interviews is a barrier.30-33 Future studies are 
needed to develop different approaches to combine 
data even when different reference standards are 
used while capitalising on the substantial amount of 
individual participant data we have collected. Also, 
head-to-head studies for commonly used screening 
tools for depression are needed.
In this study, we found that a HADS-D cut-off value 
of seven or higher maximised combined sensitivity 
and specificity among primary studies that used semi-
structured interviews. A cut-off value of eight or higher 
had similar combined sensitivity and specificity but was 
less sensitive and more specific. Other cut-off values 
could be used in clinical practice or trials to prioritise 
sensitivity or specificity. For example, if a clinician 
intends to use the HADS-D only to identify medically ill 
patients with high depressive symptom levels, higher 
cut-off values could be used to reduce false positives. 
On the other hand, if the HADS-D is used to capture all 
patients who might meet the diagnostic criteria based 
on further assessment, lower cut-off values could be 
used to avoid false negatives. Based on the results of 
our IPDMA, a web based knowledge translation tool 
(depressionscreening100.com/hads-d) was developed 
to estimate expected numbers of positive screens, and 
true and false screening outcomes. Clinicians and 
researchers who consider screening for depression 
with the HADS-D can refer to this tool.
Recommendations for routine screening for depres-
sion in primary care differ by country. Screening is not 
directly recommended in the UK, but recommendations 
from NICE suggest that clinicians might consider asking 
screening questions.7 22 Screening is recommended in 
the United States13 but not in Canada. The Canadian 
Task Force on Preventive Health Care has raised 
concerns about the lack of evidence from trials 
showing benefit, and about adverse outcomes and the 
use of scarce healthcare resources.65 In some countries, 
specific recommendations for screening in people with 
a physical illness have been made.66 Well designed 
trials evaluating the effects of screening across a range 
of cut-off scores are needed to determine if screening 
improves mental health outcomes while minimising 
harm and unnecessary use of resources. Ideally, trials 
would also help us to understand how different cut-off 
values on the HADS-D might influence results.
strengths and limitations of the study
To our knowledge, ours is the first IPDMA that has 
analysed the diagnostic accuracy of the HADS-D to 
detect major depression. Strengths of the study include 
the large sample size, inclusion of results from all cut-
off values from all studies (rather than only those 
published), and assessment of the accuracy of the 
HADS-D separately across reference standards and by 
participant subgroups.
This study has several limitations. Firstly, because 
of the time required in IPDMAs for updating searches, 
obtaining primary datasets, and cleaning and syn-
thesising new datasets, the search was not updated 
after 25 October 2018, and so more recently published 
studies were not included. Secondly, primary data 
from 66 of 158 published eligible datasets (42%) 
were not included but 50 (76%) of these studies did 
not publish eligible estimates of diagnostic accuracy 
(supplementary table B2). 
Thirdly, moderate heterogeneity was found 
across studies, which improved in most cases when 
subgroups were considered. Methods for estimating 
and interpreting heterogeneity in meta-analyses 
of test accuracy are not well established, and no 
recognised guidelines exist for interpretating the 
results of the quantitative metrics that we used. 
High heterogeneity in meta-analyses of test accuracy 
studies is common.36 60 Subgroup analyses could not 
be conducted based on medical comorbidities, with 
the exception of a diagnosis of cancer, as specified in 
the study protocol, because other than the subgroup 
of cancer patients (5805 participants with a diagnosis 
of cancer, 27 studies involved cancer patients), none 
of the disease based subgroups were large enough. 
Subgroup analyses on country and language also 
could not be conducted because many countries and 
languages were represented in a few primary studies. 
For example, studies that used 19 different languages 
were included in our IPDMA but most were represented 














































Fig 3 | nomograms of positive and negative predictive values for cut-off values of seven 
or higher, eight or higher, and 11 or higher of the hospital anxiety and Depression 
scale Depression subscale (haDs-D) for a prevalence of major depression of 5-25%, 
with semi-structured diagnostic interviews as reference standard
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Fourthly, many studies included in the meta-
analysis did not explicitly exclude participants who 
might have already been diagnosed or receiving care 
for depression, although we found no statistically 
significant differences between analyses of partici-
pants verified as not currently diagnosed or receiving 
treatment for depression and analyses of all 
participants, including those without this information. 
Fifthly, studies in the IPDMA were categorised based 
on the interview conducted but interviews might not 
have been consistently carried out in the way intended. 
Among 57 studies that used semi-structured interviews, 
11 were rated as unclear for the qualification of the 
person who conducted the interview. The use of non-
qualified interviewers might have reduced differences 
in estimates of accuracy across reference standard 
categories. Nonetheless, accuracy was highest when 
compared with semi-structured interview at a cut-
off value of seven or higher, although the difference 
from other reference standards was not statistically 
significant across all cut-off values. Lastly, sensitivity 
analyses including only studies with a low risk of bias 
rating across all QUADAS-2 domains could not be 
conducted because of the small number of studies with 
all low ratings.
conclusions
In this IPDMA, we found that combined sensitivity and 
specificity for the HADS-D was maximised at a cut-
off value of seven or higher, which was similar to the 
summed values for a cut-off value of eight or higher. 
Accuracy was not significantly different across all cut-
off values based on reference standards or participant 
characteristics, including age, sex, diagnosis of cancer, 
human development index levels, and recruitment 
setting of participants. Clinicians and researchers who 
consider screening for depression with the HADS-D 
can refer to depressionscreening100.com/hads-d to 
identify alternative cut-off values if sensitivity or 
specificity is a priority in clinical practice or trials. 
Well designed trials are needed to determine whether 
screening with the HADS-D improves mental health 
outcomes and minimises harm and use of resources.
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depressionscreening100.com/hads-d. The tool allows clinicians to 
estimate the expected number of positive screens and true and false 
screening outcomes based on study results.
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